Robert L. Krigel, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Interferon-alpha has recently been approved by the Food and Drug Administration for treatment of Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). This approval was based on evidence showing activity of this agent in this disease in studies that confirm that only high doses were effective. As Groopman and Scadden (1) pointed out, the activity of this agent is low in patients with poor prognostic indicators (previous opportunistic infection, presence of systemic symptoms, and low CD4 lymphocyte counts). In fact, no treatment, including interferon, has been shown to alter the natural history of this disease although
Krigel RL. Kaposi Sarcoma and Alpha-Interferon Therapy. Ann Intern Med. ;111:185–187. doi: 10.7326/0003-4819-111-2-185_2
Download citation file:
Published: Ann Intern Med. 1989;111(2):185-187.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use